Diabetes Care, Vol 17, Issue 10 1093-1099, Copyright © 1994 by American Diabetes Association

ARTICLES

Effect of metformin on postprandial lipemia in patients with fairly to poorly controlled NIDDM

J Jeppesen, MY Zhou, YD Chen and GM Reaven
Department of Medicine, Stanford University School of Medicine, California.

OBJECTIVE--To quantify the effect of metformin on the metabolism of triglyceride (TG)-rich lipoprotein of intestinal origin in patients with non-insulin-dependent diabetes mellitus (NIDDM) who had responded to sulfonylurea but still had fasting hyperglycemia. RESEARCH DESIGN AND METHODS--Sixteen patients with NIDDM who had demonstrated a fall in fasting plasma glucose concentration > 2.2 mmol/l in response to glipizide treatment but continued to have fasting plasma glucose concentrations > 8.3 mmol/l were studied. Fasting glucose, GHb, lipid and lipoprotein concentrations were determined, and resistance to insulin-mediated glucose disposal was estimated by measuring the steady-state plasma glucose (SSPG) concentration at the end of a 180-min infusion of somatostatin, glucose, and insulin. In addition, plasma glucose, insulin, and TG concentrations were measured at frequent intervals from 0800 to 2400, with patients eating breakfast at 0800 and lunch at 1200. Vitamin A was also given at lunch, and the retinyl ester content in plasma and in chylomicron (Svedberg flotation constant [Sf] > 400) and the chylomicron remnant (Sf 20-400) fractions were used to quantify the concentration of postprandial intestinal TG-rich lipoprotein from 1200 to 2400. RESULTS--Fasting plasma glucose concentrations (6.8 +/- 0.4 vs. 10.5 +/- 0.4 mmol/l), GHb levels (7.9 +/- 0.3 vs. 10.8 +/- 0.5%), and day-long plasma glucose concentrations were all significantly lower after metformin treatment (P < 0.001), which was associated with a significant (P < 0.001) fall in SSPG concentration (11.0 +/- 0.9 to 9.6 +/- 0.6 mmol/l). In addition, postprandial concentrations of glucose, insulin, free fatty acids, and TG were lower (P < 0.001) following metformin treatment. Postprandial retinyl ester concentrations were also lower in plasma by 33 +/- 5.7% (P < 0.001) and in both the chylomicron (32 +/- 7.2%, P < 0.001) and chylomicron remnant (26 +/- 7.0%, P < 0.005) fractions. CONCLUSIONS--Addition of metformin to sulfonylurea-treated patients with NIDDM with less than optimal glycemic control was associated with improved glycemic control, lower postprandial insulin and TG concentrations, and a decrease in postprandial concentration of TG-rich lipoproteins of intestinal origin. All of these changes might be expected to decrease risk of coronary heart disease.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				S. S Lund, L. Tarnow, M. Frandsen, U. M Smidt, O. Pedersen, H.-H. Parving, and A. A Vaag Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes Eur. J. Endocrinol., January 1, 2008; 158(1): 35 - 46. [Abstract] [Full Text] [PDF]

				T. L. Skaer, D. A. Sclar, and L. M. Robison Trends in the Prescribing of Oral Agents for the Management of Type 2 Diabetes Mellitus in the United States, 1990-2001: Does Type of Insurance Influence Access to Innovation? The Diabetes Educator, November 1, 2006; 32(6): 940 - 953. [Abstract] [Full Text] [PDF]

				J. P.H. van Wijk, E. J.P. de Koning, M. Castro Cabezas, and T. J. Rabelink Rosiglitazone Improves Postprandial Triglyceride and Free Fatty Acid Metabolism in Type 2 Diabetes Diabetes Care, April 1, 2005; 28(4): 844 - 849. [Abstract] [Full Text] [PDF]

				M E Tushuizen, M Diamant, and R J Heine Postprandial dysmetabolism and cardiovascular disease in type 2 diabetes Postgrad. Med. J., January 1, 2005; 81(951): 1 - 6. [Abstract] [Full Text] [PDF]

				S. R. Salpeter, E. Greyber, G. A. Pasternak, and E. E. Salpeter Risk of Fatal and Nonfatal Lactic Acidosis With Metformin Use in Type 2 Diabetes Mellitus: Systematic Review and Meta-analysis Arch Intern Med, November 24, 2003; 163(21): 2594 - 2602. [Abstract] [Full Text] [PDF]

				R. T. Hurst and R. W. Lee Increased Incidence of Coronary Atherosclerosis in Type 2 Diabetes Mellitus: Mechanisms and Management Ann Intern Med, November 18, 2003; 139(10): 824 - 834. [Abstract] [Full Text] [PDF]

				Z. T. Bloomgarden Treatment of Type 2 Diabetes: The American Association of Clinical Endocrinologists Meeting, May 2002 Diabetes Care, September 1, 2002; 25(9): 1644 - 1649. [Full Text] [PDF]

				L. S. Hermann and N. Wiernsperger Impaired glucose tolerance and metformin: clinical and mechanistic aspects The British Journal of Diabetes & Vascular Disease, May 1, 2002; 2(3): 177 - 183. [Abstract] [PDF]

				T. P. Erlinger and F. L. Brancati Postchallenge Hyperglycemia in a National Sample of U.S. Adults With Type 2 Diabetes Diabetes Care, October 1, 2001; 24(10): 1734 - 1738. [Abstract] [Full Text] [PDF]

				J. H. Scarpello Review: Optimal dosing strategies for maximising the clinical response to metformin in type 2 diabetes The British Journal of Diabetes & Vascular Disease, January 1, 2001; 1(1): 28 - 36. [Abstract] [PDF]

				M. Axelsen, P. Lonnroth, R. A. Lenner, M.-R. Taskinen, and U. Smith Suppression of nocturnal fatty acid concentrations by bedtime carbohydrate supplement in type 2 diabetes: effects on insulin sensitivity, lipids, and glycemic control Am. J. Clinical Nutrition, May 1, 2000; 71(5): 1108 - 1114. [Abstract] [Full Text] [PDF]

				R. A. DeFronzo Pharmacologic Therapy for Type 2 Diabetes Mellitus Ann Intern Med, August 17, 1999; 131(4): 281 - 303. [Abstract] [Full Text] [PDF]

				M. Carantoni, F. Abbasi, F. Warmerdam, M. Klebanov, P.-W. Wang, Y.-D. I. Chen, S. Azhar, and G. M. Reaven Relationship Between Insulin Resistance and Partially Oxidized LDL Particles in Healthy, Nondiabetic Volunteers Arterioscler. Thromb. Vasc. Biol., May 1, 1998; 18(5): 762 - 767. [Abstract] [Full Text] [PDF]

				B. Saulie, J. White, and R. K. Campbell Pharmacy Update: Metformin in the Treatment of Non-Insulin-Dependent Diabetes Mellitus The Diabetes Educator, January 1, 1995; 21(5): 441 - 445. [PDF]

				J. J. Tanja Jon J. Tanja, RPh, Ms, Fascp; Theresa M. Langlass, RPh, PharmD The Diabetes Educator, January 1, 1995; 21(6): 509 - 514. [PDF]